AUR103 + azacitidine

AUR103 + azacitidine is an investigational combination therapy under clinical development for hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). **AUR103** is a first-in-class, oral small molecule inhibitor of CD47, a receptor that mediates anti-phagocytic signaling and enables tumor cells to evade macrophage-mediated clearance. **Azacitidine** is a pyrimidine nucleoside analog and a DNA methyltransferase inhibitor, used clinically as a hypomethylating agent to induce cytotoxicity in abnormal hematopoietic cells and restore normal gene expression via epigenetic modulation. The combination aims to exploit complementary mechanisms: azacitidine induces cell death and immune-stimulatory changes, while AUR103 blocks the "don't eat me" CD47 signal to promote macrophage phagocytosis of cancer cells[1][2][4][6].

Brand names

Azacitidine AccordAzacitidine BetapharmAzacitidine KabiAzacitidine Mylan

Other names

azacitidine